MIT Technology Review Introduces Innovations in AI Drug Discovery

AI has established itself as core infrastructure for new drug development. Artificial intelligence (AI) and machine learning models are being applied to the process of discovering drug candidates, significantly shortening development timelines that previously took years. Drug development is a field characterized by high failure rates and requiring massive costs and investments for design and development. In particular, engineered protein (biologic) therapies are more difficult to develop than synthetic chemistry due to their complexity, which has served as the backdrop for the introduction of AI technology.

Pharmaceutical companies, such as AstraZeneca, are strengthening every step from design to manufacturing, testing, and analysis through computer-based processes. By generating candidate molecules and computationally predicting priorities, they are shortening work cycles and enhancing productivity and innovation.

Researchers are using AI to narrow down and refine vast molecular combination options beyond the scope of what humans can systematically explore, obtaining faster feedback by concentrating laboratory resources only on selected top candidates.